https://www.yiliao.com/index.php?action=history&feed=atom&title=%E7%BB%86%E8%83%9E%E5%9B%A0%E5%AD%90%E9%A3%8E%E6%9A%B4_%28CRS%29
细胞因子风暴 (CRS) - 版本历史
2026-04-21T05:48:03Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E7%BB%86%E8%83%9E%E5%9B%A0%E5%AD%90%E9%A3%8E%E6%9A%B4_(CRS)&diff=311304&oldid=prev
223.160.136.32：建立内容为“<div style="padding: 0 2%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2025-12-29T02:22:22Z
<p>建立内容为“<div style="padding: 0 2%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 2%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff;"><br />
<br />
<div style="margin-bottom: 20px; border-bottom: 1px solid #f1f5f9; padding-bottom: 15px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155;"><br />
<strong>细胞因子释放综合征</strong>（Cytokine Release Syndrome, CRS）是一种由免疫应答剧烈激活引发的全身性炎症反应。其核心特征是血液中促炎细胞因子（如 [[IL-6]]、[[IFN-γ]]、[[TNF-α]]）水平爆发式升高。在[[细胞治疗]]中，CRS 往往由效应 T 细胞与宿主[[巨噬细胞]]之间的交互作用引起，临床表现涵盖了从轻微发热到致命性的多器官衰竭及[[低血压]]。目前，国际广泛采用 **ASTCT 分级指南** 进行临床风险管理。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible" style="width: 100%; max-width: 340px; margin: 0 auto 30px auto; border: 1px solid #cbd5e1; border-radius: 12px; background-color: #ffffff; box-shadow: 0 10px 25px rgba(0,0,0,0.08); overflow: hidden;"><br />
<br />
<div style="padding: 18px 15px; color: #ffffff; background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.25em; font-weight: bold; letter-spacing: 1px; text-decoration: none !important;">CRS · 临床毒性管理</div><br />
<div style="font-size: 0.75em; opacity: 0.8; margin-top: 4px; white-space: nowrap; text-decoration: none !important;">Cytokine Release Syndrome (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 35px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 20px; padding: 25px; box-shadow: 0 4px 10px rgba(0,0,0,0.03);"><br />
[[文件:CRS_Mechanism_Icon.png|110px|细胞因子风暴病理机制]]<br />
</div><br />
<div style="font-size: 0.85em; color: #64748b; margin-top: 15px; font-weight: 600;">T 细胞-巨噬细胞级联激活模型</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.9em;"><br />
<tr><br />
<th style="text-align: left; padding: 10px 18px; border-bottom: 1px solid #f1f5f9; color: #64748b; font-weight: 600; width: 40%; background-color: #fcfdfe;">核心驱动因子</th><br />
<td style="padding: 10px 18px; border-bottom: 1px solid #f1f5f9; color: #1e293b;">[[IL-6]], IL-1, IFN-γ</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 18px; border-bottom: 1px solid #f1f5f9; color: #64748b; font-weight: 600; background-color: #fcfdfe;">一线药物</th><br />
<td style="padding: 10px 18px; border-bottom: 1px solid #f1f5f9; color: #1e293b;">[[托珠单抗]], [[地塞米松]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 18px; color: #64748b; font-weight: 600; background-color: #fcfdfe;">分级标准</th><br />
<td style="padding: 10px 18px; color: #1e293b; font-weight: bold;">[[ASTCT 2019]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: linear-gradient(to right, #1e3a8a, #ffffff); color: #ffffff; padding: 8px 15px; border-radius: 4px; font-size: 1.2em; margin-top: 35px; text-decoration: none !important;">病理生理机制：细胞因子的瀑布效应</h2><br />
<p style="margin: 15px 0;"><br />
CRS 的发生并非单纯由效应 T 细胞驱动，而是涉及多细胞参与的“级联放大”过程：<br />
</p><br />
<ul style="padding-left: 20px; color: #475569;"><br />
<li style="margin-bottom: 10px;"><strong>启动阶段：</strong> 回输的 [[CAR-T]] 或其他免疫效应细胞识别靶抗原后迅速激活，释放 IFN-γ 和 TNF-α。</li><br />
<li style="margin-bottom: 10px;"><strong>放大阶段：</strong> 促炎因子募集并激活内源性宿主细胞，特别是[[巨噬细胞]]和单核细胞。这些细胞通过 [[NF-κB 通路]] 暴发式产生核心促炎因子 **[[IL-6]]** 和 IL-1。</li><br />
<li style="margin-bottom: 10px;"><strong>效应阶段：</strong> 高浓度的 IL-6 与受体结合，触发全身[[内皮损伤]]，导致[[毛细血管渗漏综合征]]，引发临床可见的低血压、缺氧及器官灌注不足。</li><br />
</ul><br />
<br />
<h2 style="background: linear-gradient(to right, #1e3a8a, #ffffff); color: #ffffff; padding: 8px 15px; border-radius: 4px; font-size: 1.2em; margin-top: 35px; text-decoration: none !important;">ASTCT 分级与干预逻辑</h2><br />
<p style="margin: 15px 0;"><br />
现代临床管理强调“动态分级”与“早期干预”：<br />
</p><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 85%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1px solid #e2e8f0; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #1e3a8a;"><br />
<th style="padding: 12px; border: 1px solid #e2e8f0; color: #1e3a8a;">级别 (Grade)</th><br />
<th style="padding: 12px; border: 1px solid #e2e8f0; color: #1e3a8a;">临床指征 (ASTCT)</th><br />
<th style="padding: 12px; border: 1px solid #e2e8f0; color: #1e3a8a;">干预策略</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #e2e8f0; background: #fcfdfe; font-weight: bold;">1 级</td><br />
<td style="padding: 10px; border: 1px solid #e2e8f0;">发热 (≥38°C)，无血压或氧合改变。</td><br />
<td style="padding: 10px; border: 1px solid #e2e8f0;">对症治疗、严密监测。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #e2e8f0; background: #fcfdfe; font-weight: bold;">2 级</td><br />
<td style="padding: 10px; border: 1px solid #e2e8f0;">低血压 (仅需补液) 或 氧合受损。</td><br />
<td style="padding: 10px; border: 1px solid #e2e8f0;">[[托珠单抗]] ± 糖皮质激素。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #e2e8f0; background: #fcfdfe; font-weight: bold;">3/4 级</td><br />
<td style="padding: 10px; border: 1px solid #e2e8f0;">需升压药、高流量吸氧或机械通气。</td><br />
<td style="padding: 10px; border: 1px solid #e2e8f0;">大剂量激素 + 联合[[阿那白滞素]]。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: linear-gradient(to right, #1e3a8a, #ffffff); color: #ffffff; padding: 8px 15px; border-radius: 4px; font-size: 1.2em; margin-top: 35px; text-decoration: none !important;">前沿视点：预防性干预与预测标志物</h2><br />
<p style="margin: 15px 0;"><br />
针对致力于[[CAR-T]]转化的首席科学家，CRS 的研究焦点已从“治疗”转向“预测”：<br />
</p><br />
<ul style="padding-left: 20px; color: #475569;"><br />
<li style="margin-bottom: 10px;"><strong>生物标志物：</strong> 治疗后早期 **[[CRP]]**（C反应蛋白）和**铁蛋白**的倍数增长可有效预测 3 级以上 CRS 的发生风险。</li><br />
<li style="margin-bottom: 10px;"><strong>内皮保护：</strong> 监测 Ang-2/Ang-1 比例，在 CRS 早期通过维持内皮稳定性来预防向危重症演变。</li><br />
<li style="margin-bottom: 10px;"><strong>工程化优化：</strong> 研发带有“自杀开关”或可诱导式抑制元件的次世代 CAR-T，从源头控制细胞因子的释放动力学。</li><br />
</ul><br />
<br />
<div style="font-size: 0.85em; line-height: 1.8; color: #94a3b8; margin-top: 40px; border-top: 2px solid #f1f5f9; padding-top: 15px;"><br />
<p style="margin-bottom: 8px;"><br />
[1] Lee DW, et al. "ASTCT Consensus Grading for Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome." <em>BBMT</em>. 2019. <br />
<span style="color: #64748b;">(点评：全球临床管理的共识文件，统一了严重度定义与评价体系。)</span><br />
</p><br />
<p style="margin-bottom: 8px;"><br />
[2] Neelapu SS, et al. "Chimeric antigen receptor T-cell therapy — assessment and management of toxicities." <em>Nat Rev Clin Oncol</em>. 2018. <br />
<span style="color: #64748b;">(点评：深度解析了巨噬细胞作为细胞因子风暴核心放大器的病理逻辑。)</span><br />
</p><br />
<p style="margin-bottom: 8px;"><br />
[3] Norelli M, et al. "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity." <em>Nature Medicine</em>. 2018. <br />
<span style="color: #64748b;">(点评：揭示了 IL-1 在 CRS 中的启动作用，为阿那白滞素的应用提供了关键临床前依据。)</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #1e3a8a; border-radius: 8px; overflow: hidden; font-size: 0.9em;"><br />
<div style="background-color: #1e3a8a; color: #ffffff; text-align: center; font-weight: bold; padding: 12px; text-decoration: none !important;">CRS 相关领域导航</div><br />
<div style="padding: 15px; background: #ffffff; line-height: 2; text-align: center;"><br />
[[ICANS]] • [[托珠单抗]] • [[IL-6 信号轴]] • [[内皮损伤]] • [[ASTCT 分级指南]]<br />
</div><br />
</div><br />
<br />
</div></div>
223.160.136.32